Articles tagged "Rejection"

2018 American Transplant Congress
The Treatment of Antibody-Mediated Rejection in Kidney Transplantation: An Updated Systematic Review and Meta-Analysis
S. Wan,^1,2 T. Ying,^1,2 K. Wyburn,^1,2 D. Roberts,^3,4 M. Wyld,^1,2 S. Chadban.^1,2
¹Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia; ²Sydney Medical School, University of Sydney, Sydney, Australia; ³Department of Renal Medicine, Canberra Hospital and Health Services, Canberra, Australia; ⁴Medical School, Australian National University, Canberra, Australia.
Introduction: Current treatment strategies for antibody-mediated rejection (AMR) in kidney transplantation are based on low quality data from a small number of controlled trials. Novel…
2018 American Transplant Congress
Impact of a Steroid Free Immunosuppressive Regimen on Patient and Graft Outcomes in Pancreas Transplant Recipients
M. Cote,¹ C. Rogers,¹ K. Khwaja,² A. Evenson,² M. Pavlakis,² K. Richards.¹
¹Pharmacy, Beth Israel Deaconess Medical Center, Boston, MA; ²Transplant Institute, Beth Israel Deaconess Medical Center, Boston, MA.
Steroids have been an important component of maintenance immunosuppression in solid organ transplant, but their adverse effect profile has led to the development of steroid…
2018 American Transplant Congress
An In Vitro Model of Human Antibody-Mediated Rejection Depicts Key Role for NK Cells
L. Hidalgo,¹ M. Racape,² A. Loupy,² C. Lefaucheur.²
¹Lab. Med. and Pathology, University of Alberta, Edmonton, AB, Canada; ²Paris Cardiovascular Research Center INSERM, Paris, France.
AIM: Antibody-mediated rejection (ABMR) is the leading cause of kidney allograft loss but its immune mechanisms are incompletely understood. We sought to examine key interactions…
2018 American Transplant Congress
Distribution of Biopsy Proven Acute Rejection in a Large Pediatric Kidney Transplant Program: A Four Year Experience
C. Varnell, Jr.,¹ A. Carle,^2,3 D. Hooper.^1,2,3
¹Division of Nephrology & Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; ²James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; ³Department of Pediatrics, University of Cincinnati, Cincinnati, OH.
Introduction: Kidney biopsy is the gold standard for diagnosing rejection, transplant glomerulopathy, and other pathology after transplantation. We aimed to understand the distribution of Banff…
2018 American Transplant Congress
Urinary Proteomic Biomarkers for Prediction of Chronic Antibody-Mediated Rejection in Kidney Transplant Recipients
H. Jung,¹ K. Jeong,¹ J-.H. Lim,¹ J. Choi,¹ J-.H. Cho,¹ S-.H. Park,¹ Y-.L. Kim,¹ C-.H. Lee,² M-.C. Baek,² B. Chung,³ S-.H. Lee,⁴ C-.D. Kim.¹
¹Internal Medicine, Kyungpook National University School of Medicine, Daegu, Republic of Korea; ²Molecular Medicine, Kyungpook National University School of Medicine, Daegu, Republic of Korea; ³Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea; ⁴Internal Medicine, College of Medicine, Kyung Hee University, Seoul, Republic of Korea.
Background: Chronic antibody-mediated rejection (CAMR) is a challenging issue associated with allograft loss in kidney transplant recipients (KTRs) undergoing long-term follow-up. Changes in the urinary…
2018 American Transplant Congress
The Impact of Conversion from Immediate Release Twice-Daily Tacrolimus (Prograf®) to Once-Daily Extended Release Tacrolimus (Envarsus®) in Liver Transplant Recipients
M. Del Gaudio,¹ M. Cescon,¹ M. Ravaioli,¹ V. Bertuzzo,¹ C. Zanfi,¹ M. Serenari,¹ L. Maroni,¹ C. Morelli,² A. Pinna.¹
¹Organ Insufficiency and Transplantation, S.Orsola Hospital General Surgery and Transplantation Unit Prof. A.D. Pinna, Bologna, Italy; ²Organ Insufficiency and Transplantation, S. Orsola Hospital Organ Insufficiency and Internal Medicine Morelli, Bologna, Italy.
The safety and efficacy of substitution with a novel once-daily extended-release tacrolimus (LCPT;Envarsus®)to immediate-release tacrolimus (IR-Tac, Prograf®) twice daily in liver transplant patients have not…
2018 American Transplant Congress
Clinical Significance of Isolated v-Lesions in Kidney Transplantation
A. Georgalis,¹ C. Wehmeier,¹ P. Hirt-Minkowski,¹ G. Hönger,¹ H. Hopfer,² J. Steiger,¹ S. Schaub,¹ P. Amico.¹
¹Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland; ²Institute for Pathology, University Hospital Basel, Basel, Switzerland.
Background: Arteritis without significant tubulo-interstitial inflammation (v1-3, but i≤1 and t≤1) is referred by the 10th Banff conference as 'isolated v-lesions'. The clinical significance of…
2018 American Transplant Congress
Effect of Belatacept on Late Acute Rejection Episodes and Graft Loss in Young Adults between the Ages of 18-24 Years: Post-Hoc Analysis of BENEFIT Study
A. Moudgil.
Nephrology, Children National Health System, Washington, DC.
Background: Recent data suggests higher incidence of late acute rejection (LAR) in young adults (18-24 years of age) causing graft loss just like adolescents due…
2018 American Transplant Congress
Allogeneic Mesenchymal Stem Cells as Induction Therapy Are Safe and Feasible in Renal Allografts: Pilot Results of a Multicenter Randomized Controlled Trial
Q. Sun,¹ F. Han,¹ M. Zhao,² R. Cao,³ D. Zhao,¹ Z. Huang,¹ L. Hong,¹ Y. Peng,¹ Q. Sun.¹
¹Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; ²Zhujiang Hospital, Southern Medical University, Guangzhou, China; ³Second Affiliated Hospital, Guangzhou Traditional Chinese Medicine University, Guangzhou, China.
Background: Delayed graft function (DGF) and acute rejection lead to adverse effects on graft outcomes. Optimal induction intervention should include both renal structure injury repair…
2018 American Transplant Congress
Donor-Derived Cell-Free DNA Identifies Antibody-Mediated Rejection with Graft Injury in DSA-Positive Kidney Transplant Recipients
S. Jordan,¹ S. Bunnapradist,² J. Bromberg,³ A. Langone,⁴ D. Hiller,⁵ J. Yee,⁵ J. Sninsky,⁵ R. Woodward,⁵ A. Matas.⁶
¹Cedars-Sinai Medical Center, Los Angeles, CA; ²UCLA, Los Angeles, CA; ³University of Maryland School of Medicine, Baltimore, MD; ⁴Vanerbilt University Medical Center, Nashville, TN; ⁵CareDx, Brisbane, CA; ⁶University of Minnesota School of Medicine, Minneapolis, MN.
Purpose: Donor-derived cell-free DNA (dd-cfDNA) discriminates active rejection in kidney transplant patients. Donor-specific antibodies (DSA) to HLA antigens are associated with risk of antibody-mediated rejection…